Takeda Pharmaceutical (TAK) Projected to Announce Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is anticipated to announce its Q1 2027 results before the market opens on Thursday, July 30th. Analysts expect Takeda Pharmaceutical to announce earnings of $0.1689 per share and revenue of $7.1054 billion for the quarter. Investors can check the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. On average, analysts expect Takeda Pharmaceutical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Up 1.2%

Shares of NYSE TAK opened at $17.45 on Tuesday. The firm has a market capitalization of $55.92 billion, a PE ratio of 44.75 and a beta of -0.07. The company has a current ratio of 1.09, a quick ratio of 0.60 and a debt-to-equity ratio of 0.59. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $18.90. The firm’s 50-day moving average is $16.19 and its 200-day moving average is $17.04.

Institutional Trading of Takeda Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust lifted its holdings in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after acquiring an additional 2,328 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after acquiring an additional 1,292 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Takeda Pharmaceutical during the third quarter worth about $74,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth about $101,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TAK. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.